News By Tag
News By Location
Asthma and COPD Patient Numbers on the Rise Globally
Industry leaders, key stakeholders to gather at IQPC’s 3rd Asthma & COPD Conference to address novel discoveries and treatment programs within the respiratory drug arena
The 2010 Asthma Burden in Medicaid Population report details the burden of asthma among children (0-17) and adults (18-64) in the Medicaid population for 2004-2008 in Pennsylvania. The report reveals that for the entire five-year period, annual paid claims for asthma emergency room visits and office visits increased. Further, the total cost of asthma medications and asthma related services among Medicaid recipients also increased for the five-year period. The report is available in its entirety here:
Globally, asthma affects an estimated 235 million people, and as that number grows, so does the demand for drugs to cope with the illness. GlobalData, a London-based research firm, says the global asthma market will expand from around $12.4 billion in 2009 to $14 billion by 2017.
The 3rd Asthma & COPD provides an opportunity to improve competitiveness through targeted delivery to increase bioavailability of therapeutics and reduce the attrition rate. The conference also offers insights into reformulating approved drugs as patents expire. Other notable program highlights include:
• Case study examples of successful initiatives
• Opportunities to interact with stakeholders from both R&D and in the clinic
• Creating a well-balanced treatment program
• Emerging treatment paradigms within COPD drug development
• New prevention programs to promote education and reduce prevalence of asthma and COPD
Key industry leaders and stakeholders from Pearl Therapeutics, Actimis Pharmaceuticals, Sunstein Kann Murphy & Timbers, the New York and Pennsylvania Departments of Health, Merck & Co. the University of Texas, Austin, and more will share insights at the conference.
For more information on the 3rd Asthma & COPD Conferencee, please visit http://www.asthmacopdevent.com or contact Program Director Robert Littlefield at Robert.Littlefield@
# # #